PLoS ONE (Jan 2018)

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.

  • Juliette M Bouyssou,
  • Chia-Jen Liu,
  • Mark Bustoros,
  • Romanos Sklavenitis-Pistofidis,
  • Yosra Aljawai,
  • Salomon Manier,
  • Amir Yosef,
  • Antonio Sacco,
  • Katsutoshi Kokubun,
  • Shokichi Tsukamoto,
  • Adriana Perilla Glen,
  • Daisy Huynh,
  • Jorge J Castillo,
  • Steven P Treon,
  • Véronique Leblond,
  • Olivier Hermine,
  • Aldo M Roccaro,
  • Irene M Ghobrial,
  • Marzia Capelletti

DOI
https://doi.org/10.1371/journal.pone.0204589
Journal volume & issue
Vol. 13, no. 10
p. e0204589

Abstract

Read online

Waldenström Macroglobulinemia (WM) is a low-grade B-cell lymphoma characterized by disease progression from IgM MGUS to asymptomatic and then symptomatic disease states. We profiled exosomes from the peripheral blood of patients with WM at different stages (30 smoldering/asymptomatic WM, 44 symptomatic WM samples and 10 healthy controls) to define their role as potential biomarkers of disease progression. In this study, we showed that circulating exosomes and their miRNA content represent unique markers of the tumor and its microenvironment. We observed similar levels of miRNAs in exosomes from patients with asymptomatic (smoldering) and symptomatic WM, suggesting that environmental and clonal changes occur in patients at early stages of disease progression before symptoms occur. Moreover, we identified a small group of miRNAs whose expression correlated directly or inversely with the disease status of patients, notably the known tumor suppressor miRNAs let-7d and the oncogene miR-21 as well as miR-192 and miR-320b. The study of these miRNAs' specific effect in WM cells could help us gain further insights on the mechanisms underlying WM pathogenesis and reveal their potential as novel therapeutic targets for this disease.